Nimel Mental Health is now certified to provide SPRAVATO®, a nasal spray approved for use, in conjunction with an oral antidepressant, in adults with treatment-resistant depression or depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

SPRAVATO® is now approved as the first and only treatment used as monotherapy for adults living with treatment-resistant depression.

Our doctors and nurses proactively coordinate your care and will ensure an open line of communication with your referring doctor to monitor your progress. In addition, our care team will guide you through your journey, clearly explaining what to expect during your SPRAVATO® treatment sessions. We will also work with your insurance provider to confirm your coverage and your costs prior to your treatment with SPRAVATO®.

To learn more about our treatment center and how we can work with you, please contact us today to start your treatment journey with SPRAVATO®.